ANL (Adlai Nortye) FCF Margin %: -366.62% (As of Dec. 2025)


What is Adlai Nortye FCF Margin %?

Adlai Nortye ANL -1.57% FCF Margin % is -366.62% as of Dec. 2025. The stock has 7 warning signs investors should review. Among 959 Biotechnology companies, Adlai Nortye ranks worse than 75.7% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Adlai Nortye's Free Cash Flow for the six months ended in Dec. 2025 was $-18.33 Mil. Adlai Nortye's Revenue for the six months ended in Dec. 2025 was $5.00 Mil. Therefore, Adlai Nortye's FCF Margin % for the quarter that ended in Dec. 2025 was -366.62%.

As of today, Adlai Nortye's current FCF Yield % is -5.19%.

The historical rank and industry rank for Adlai Nortye's FCF Margin % or its related term are showing as below:

ANL' s FCF Margin % Range Over the Past 10 Years
Min: -672.78   Med: -340.93   Max: -9.08
Current: -669.04

During the past 5 years, the highest FCF Margin % of Adlai Nortye was -9.08%. The lowest was -672.78%. And the median was -340.93%.

ANL's FCF Margin % is ranked worse than
75.7% of 959 companies
in the Biotechnology industry
Industry Median: -84.65 vs ANL: -669.04

Adlai Nortye FCF Margin % Related Terms

Adlai Nortye FCF Margin % Historical Data

* Premium members only.

The historical data trend for Adlai Nortye's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adlai Nortye FCF Margin % Chart

Adlai Nortye Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
-9.08 0.00 0.00 0.00 -672.78

Adlai Nortye Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
FCF Margin % Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 -366.62

ANL vs PHAT, AURA, RLMD: FCF Margin % Comparison

For the Biotechnology subindustry, Adlai Nortye's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adlai Nortye FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adlai Nortye's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Adlai Nortye's FCF Margin % falls into.


Adlai Nortye FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Adlai Nortye's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-33.639/5
=-672.78 %

Adlai Nortye's FCF Margin for the quarter that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-18.331/5
=-366.62 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -366.62% mean?
Adlai Nortye (ANL) has a FCF Margin % of -366.62% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Adlai Nortye and its competitors. According to the industry distribution chart, Adlai Nortye ranks #726 out of 959 companies in the Biotechnology industry, placing it in the top 75.7%.
Is Adlai Nortye's FCF Margin % too high?
Adlai Nortye's current FCF Margin % is -366.62%. Based on the distribution chart, Adlai Nortye ranks #726 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Adlai Nortye's FCF Margin % compare to PHAT and AURA?
According to the Biotechnology industry distribution chart, Adlai Nortye ranks #726 out of 959 companies for FCF Margin %. This places Adlai Nortye in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Adlai Nortye and its competitors. Adlai Nortye's current FCF Margin % is -366.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adlai Nortye stock overvalued right now?
Adlai Nortye (ANL) has a current FCF Margin % of -366.62%. The current FCF Margin % is -366.62%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Adlai Nortye (ANL), the current FCF Margin % is -366.62% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adlai Nortye Business Description

Other Exchanges N2U0:Germany
Address 685 US Highway 1, New Jersey Biotechnology Development Center, 2nd Floor, North Brunswick, NJ, USA, 08902
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.